Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission
出版年份 2013 全文链接
标题
Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission
作者
关键词
-
出版物
Blood Cancer Journal
Volume 3, Issue 11, Pages e164-e164
出版商
Springer Nature
发表日期
2013-11-29
DOI
10.1038/bcj.2013.62
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation
- (2013) A Garfall et al. BONE MARROW TRANSPLANTATION
- NK Cells—From Bench to Clinic
- (2012) William J. Murphy et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant
- (2012) Andrea Velardi et al. CURRENT OPINION IN HEMATOLOGY
- HLA-C–Dependent Prevention of Leukemia Relapse by Donor ActivatingKIR2DS1
- (2012) Jeffrey M. Venstrom et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of natural killer cells in hematopoietic stem cell transplantation
- (2011) Panagiotis D. Tsirigotis et al. ANNALS OF MEDICINE
- Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation
- (2011) Caron A. Jacobson et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Use of NK cell activity in cure by transplant
- (2011) Wing Leung BRITISH JOURNAL OF HAEMATOLOGY
- An overview of the progress on double umbilical cord blood transplantation
- (2011) A. Sideri et al. HAEMATOLOGICA
- Is there an impact of killer cell immunoglobulin-like receptors and KIR-ligand incompatibilities on outcomes after unrelated cord blood stem cell transplantation?
- (2010) Roel Willemze et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia
- (2010) S. Cooley et al. BLOOD
- Killer Ig-like receptor-mediated control of natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation
- (2010) L. Moretta et al. BLOOD
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research
- (2009) Sergio Giralt et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Negative effect of KIR alloreactivity in recipients of umbilical cord blood transplant depends on transplantation conditioning intensity
- (2009) C. G. Brunstein et al. BLOOD
- Increased number of CD16+CD56dim NK cells in peripheral blood mononuclear cells after allogeneic cord blood transplantation
- (2009) Junji Tanaka et al. HUMAN IMMUNOLOGY
- Natural killer cells: integrating diversity with function
- (2009) Kuldeep Cheent et al. IMMUNOLOGY
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia
- (2009) R Willemze et al. LEUKEMIA
- Essential function for SAP family adaptors in the surveillance of hematopoietic cells by natural killer cells
- (2009) Zhongjun Dong et al. NATURE IMMUNOLOGY
- MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response
- (2008) M. Yawata et al. BLOOD
- The killer's kiss: the many functions of NK cell immunological synapses
- (2008) Konrad Krzewski et al. CURRENT OPINION IN CELL BIOLOGY
- Donor Killer Immunoglobulin-Like Receptor (KIR) Genotype-Patient Cognate KIR Ligand Combination and Antithymocyte Globulin Preadministration Are Critical Factors in Outcome of HLA-C-KIR Ligand-Mismatched T Cell–Replete Unrelated Bone Marrow Transplantation
- (2007) Toshio Yabe et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started